Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model

被引：7

作者：

Matsumoto, Shuhei ^{[1
]}

Kanazawa, Sachi ^{[2
]}

Sato, Takafumi ^{[2
]}

Yamano, Yoshinori ^{[2
]}

机构：

[1] Shionogi & Co Ltd, Business Dev, Osaka, Japan

[2] Shionogi & Co Ltd, Drug Discovery & Dis Res Lab, Osaka, Japan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2020年 / 64卷 / 11期

关键词：

cefiderocol; carbapenem resistant; Enterobacterales; Acinetobacter baumannii; chemostat model; nonfermenters; COLISTIN;

D O I：

10.1128/AAC.01128-20

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Activities of cefiderocol under simulated human plasma concentrations at the recommended dosing regimen of 2 g every 8 h with a 3-h infusion were evaluated using an in vitro chemostat model. Against a total of 6 meropenem-resistant Gram-negative strains with cefiderocol MICs of 0.5 to 4 mu g/ml, including metallo-beta-lactamase producers and carbapenem-resistant Acinetobacter baumannii, cefiderocol treatment showed a bactericidal effect within 8 h and sustained efficacy with no marked bacterial regrowth over 24 h.

引用

收藏

页数：5

相关论文

共 19 条

[11] Shifting Gears: The Future of Polymyxin Antibiotics [J].

Lenhard, Justin R. ;

Bulman, Zackery P. ;

Tsuji, Brian T. ;

Kaye, Keith S. .

ANTIBIOTICS-BASEL, 2019, 8 (02)

[12]

Monogue ML, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01022-17, 10.1128/aac.01022-17]

[13] In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models [J].

Nakamura, Rio ;

Ito-Horiyama, Tsukasa ;

Takemura, Miki ;

Toba, Shinsuke ;

Matsumoto, Shuhei ;

Ikehara, Tatsuya ;

Tsuji, Masakatsu ;

Sato, Takafumi ;

Yamano, Yoshinori .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (09)

[14] The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms [J].

Noval, Mandee ;

Banoub, Mary ;

Claeys, Kimberly C. ;

Heil, Emily .

CURRENT INFECTIOUS DISEASE REPORTS, 2020, 22 (01)

[15] Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria [J].

Plachouras, D. ;

Karvanen, M. ;

Friberg, L. E. ;

Papadomichelakis, E. ;

Antoniadou, A. ;

Tsangaris, I. ;

Karaiskos, I. ;

Poulakou, G. ;

Kontopidou, F. ;

Armaganidis, A. ;

Cars, O. ;

Giamarellou, H. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) :3430-3436

[16] Closing the Loop-A Colistin Clinical Study to Confirm Dosing Recommendations From PK/PD Modeling [J].

Roberts, Jason A. ;

Lipman, Jeffrey .

CLINICAL INFECTIOUS DISEASES, 2012, 54 (12) :1727-1729

[17] Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin [J].

Sato, Takafumi ;

Yamawaki, Kenji .

CLINICAL INFECTIOUS DISEASES, 2019, 69 :538-543

[18] In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria [J].

Yamano, Yoshinori .

CLINICAL INFECTIOUS DISEASES, 2019, 69 :544-551

[19] Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli [J].

Zhanel, George G. ;

Golden, Alyssa R. ;

Zelenitsky, Sheryl ;

Wiebe, Karyn ;

Lawrence, Courtney K. ;

Adam, Heather J. ;

Idowu, Temilolu ;

Domalaon, Ronald ;

Schweizer, Frank ;

Zhanel, Michael A. ;

Lagace-Wiens, Philippe R. S. ;

Walkty, Andrew J. ;

Noreddin, Ayman ;

Lynch, Joseph P., III ;

Karlowsky, James A. .

DRUGS, 2019, 79 (03) :271-289